PPT-Evaluating cell lines as tumor models by comparison

of genomic profiles Domcke S et al Nat Commun 4 2126 Motivation Problem Genomic differences between cancer cell lines and tissue samples TCGA and CCLE provide molecular profiles for tumor samples and cell lines. Sam Kupfer and Joseph Ahmad. Background/Outline. Cancer is a group of diseases in which abnormal cells divide uncontrollably, forming tumors that interrupt the normal functioning of nearby cells and organs. c. aught in the act of invading: Their strategy for enhanced cell motility” . By Xinqi Li and Megan Roytman. Weigang . Wang, . Sumanta . Goswami, . Erik . Sahai, . Jeffrey B. . Wyckoff, . Jeffrey E. . Objectives of preclinical tests. Preclinical tests helps to. Evaluate its toxicity. A. ssess its effectiveness. Propose a pharmaceutical form. 2. Objectives (2). Preclinical studies:. Select appropriate models based on target and Mode of Action . . SOT Fall . Symposium: . New . Frontiers in Oncology Drug . Development. September 27, 2012. Jocelyn Holash. Novartis Institutes for Biomedical Research . Preclinical strategies to help better identify responder . Molecular Pathology Director: Frederick Nolte, Ph.D.. Cytogenetics and Molecular Genetics Director: . Daynna. Wolff, Ph.D.. Medical Director: Cynthia Schandl, M.D., Ph.D.. Associate Director: Julie Woolworth Hirschhorn, Ph.D.. Protein Cell Indian God of Destruction Mian WuProtein Cell Yide Mei and Mian Wu 118 Higher Education Press and Springer-Verlag Berlin Heidelberg 2012 Figure 1 The schematic representation of Siv vTABLE OF CONTENTS Page ABSTRACTDEDICATIONACKNOWLEDGEMENTS viTABLE OF CONTENTS viiLIST OF FIGURES xLIST OF TABLES xiv CHAPTER I INTRODUCTION 1 Background 1Motivation 2Objective 6 II COMPUT At diagnosis 80% of patients will present with metastasis.. Only 20% of these cases are clinically detectable.. Current imaging modalities are expensive and only detect established secondary tumors.. Séminaire. des . doctorants. William . Weens. BANG, . Inria. November. . 15th . 2011. Outline. Cancer. Systems Biology. Mathematical description. Application to liver tumor. Conclusion. Definition. 127 pISSN 2384-1095eISSN 2384-1109 Department of Radiology, Jeju National University Hospital, Jeju-si, KoreaDepartment of Pathology, Jeju National University Hospital, Jeju-si, Korea www.i-mri.org 12 New . Frontiers in Oncology Drug . Development. September 27, 2012. Jocelyn Holash. Novartis Institutes for Biomedical Research . Preclinical strategies to help better identify responder . populations in the clinic. Brian D. Halligan. 1. , Yue Chen. 1. , Antonio Oliveri. 1. , Maurice Tohme. 1. , and Elizabeth K. Speliotes. 1,2. 1. Division of Gastroenterology Department of Internal Medicine, . 2. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109 . Malhão. 1,2. , Eduardo Rocha. 1,2. , Alice Ramos. 1,2. 1 . Laboratory of Histology and Embriology, Department of Microscopy, ICBAS - Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal.. . . Daniel maina. Introduction. The use of the laboratory in evaluating the immune system should not follow a shotgun approach . but rather . should be a focused evaluation using specific testing in an orderly process based on the .